Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
Study sponsor: BioCryst Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-31Actual
Enrollment · participants28Actual
Source updated2026-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.